It's expected to make it easier for people to stay on track with their HIV medicines and to do so with more privacy. Not long ago, patients had to take multiple pills several times a day to control infection with…
Trying to close out major unfinished business, the Trump administration issued regulations Friday that could lower the prices Americans pay for many prescription drugs.
The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked.
Its maker, Gilead Sciences Inc., said Thursday that the drug is approved for people at least 12 years old who need hospitalization for their coronavirus infection.
The nearly 1 million people around the world who have lost their lives to COVID-19 have left us a gift: Through desperate efforts to save their lives, scientists now better understand how to treat and prevent the disease — and…
"That's a win as far as I'm concerned" because it suggests a first infection may protect a person from moderate to severe disease the second time around, a vaccine expert said.
The U.S. government announced this week that it had an agreement with Gilead Sciences to make the bulk of their production of remdesivir available to Americans for the next three months.
U.S. officials believe as many as 20 million Americans have contracted the coronavirus since it first arrived in the country. That's nearly 10 times as many infections as the 2.3 million cases that have been confirmed so far.
Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A cheap, widely available steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients.
Several authors of a large study that raised safety concerns about malaria drugs for coronavirus patients have retracted the report. They say independent reviewers weren't able to verify information that's been widely questioned by other scientists.
Support Provided By:
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.
Thank you. Please check your inbox to confirm.